-
Hexose Diphosphate: Applied Metabolic Workflows
2026-09-15
Use hexose diphosphate to connect carbohydrate-phosphate metabolism with ATP balance, ischemia models, and carefully controlled inflammation assays. This workflow-focused guide emphasizes water-based preparation, time-resolved metabolic measurements, and the limits of translating findings from phosphoenolpyruvate research.
-
Biotin-XX Tyramide Reagent for Cell-Surface TSA
2026-09-15
Biotin-XX Tyramide Reagent combines HRP-driven signal amplification with a membrane-impermeant design for selective cell-surface labeling in tissue sections and cells. This article translates a Drosophila stem-cell migration study into practical immunohistochemistry and in situ hybridization assay choices, with workflow parameters and troubleshooting guidance.
-
NF-κB–YAP–NLRP3 Control of Colitis Pyroptosis
2026-09-14
A 2026 study identifies an epithelial NF-κB p65–LATS1–YAP–NLRP3 axis that links inflammatory signaling to GSDMD-dependent pyroptosis in ulcerative colitis. By combining epithelial-cell assays, DSS colitis, GSDMD knockout mice, YAP overexpression, nucleoplasmic separation, and chromatin immunoprecipitation, the work positions YAP loss as a key step connecting NF-κB activation with colonic barrier injury.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-14
A 2026 FASEB Journal study developed chemically modified p21 mRNA–loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links restored nuclear p21 expression with cell-cycle suppression, DNA damage signaling, apoptosis, and reduced tumor growth in an orthotopic mouse model, while also defining important translational limitations for mRNA-LNP delivery.
-
CGRP/SP–Piezo2 Signaling in Trigeminal Neuralgia
2026-09-13
Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their rat and cellular experiments position ATP, PKC, ERK1/2, and p38 MAPK signaling as mechanistic connectors between trigeminal ganglion neurons and Merkel cells.
-
AZD8055 Practical mTOR Inhibitor Workflow
2026-09-12
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled biochemical, cellular, and animal studies of mTORC1 and mTORC2 signaling. It is suited to mechanistic cancer and metabolism research, but not to experiments requiring water-soluble dosing or direct conclusions about clinical efficacy.
-
8-Chloroadenosine in RNA Regulation Research
2026-09-12
8-Chloroadenosine is a nucleoside analog and RNA synthesis inhibitor for controlled transcriptional regulation research. Product specifications support DMSO-based preparation and cold storage, while a recent NSCLC study provides a separate RNA-stability framework involving RP3-340N1.2, IL-6, and ZC3H12A.
-
Lovastatin Workflows for Mechanistic Cell Research
2026-09-11
Lovastatin enables controlled interrogation of mevalonate depletion across proliferation, apoptosis, wound remodeling, and macrophage function. This practical guide combines product handling, staged assay design, and cross-domain lessons from floral meristem research without conflating validated mechanisms with exploratory applications.
-
ACE2–MasR–Sirt1 Signaling in Septic Cardiomyopathy
2026-09-11
The reference study identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and links pharmacological ACE2 activation with MasR–Sirt1-mediated mitochondrial biogenesis. Using Diminazene Aceturate and MLN-4760 in a mouse cecal ligation and puncture model, the authors connect mitochondrial dysfunction with cardiac inflammation, oxidative stress, apoptosis, and impaired function.
-
I-BET151 (GSK1210151A): Practical Workflow Guide
2026-09-10
I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor for studying BRD2, BRD3, and BRD4-dependent transcriptional responses in cancer biology. This guide covers compound preparation, assay planning, and quality control while clarifying that product-dossier data should not be treated as clinical, diagnostic, or directly matched paper evidence.
-
Reparixin: Decoding CXCR1/2 in Inflammation
2026-09-10
Reparixin is a CXCR1/2 inhibitor that enables mechanistic dissection of CXCL8-driven neutrophil migration and inflammatory signaling. This article connects receptor pharmacology with MRSA extracellular-vesicle research while defining the assay controls needed to distinguish tumor-cell, immune-cell, and tissue-level effects.
-
Perphenazine Workflows for Neuroimmune Research
2026-09-09
Perphenazine combines dopamine D2 receptor antagonism with a measurable mitochondrial stress phenotype, making it useful for neuropharmacology, cytotoxicity, and mechanism-led host-defense assays. This guide translates published findings into practical dosing, controls, imaging, and troubleshooting strategies for reproducible bench workflows.
-
AI-10-49 Workflow for CBFβ-SMMHC Research
2026-09-09
AI-10-49 enables mechanism-resolved acute myeloid leukemia research by linking CBFβ-SMMHC–RUNX1 disruption to chromatin recovery, transcriptional changes, and leukemia cell survival. This practical workflow combines target engagement, chromatin immunoprecipitation, N-MYC/eIF4G1 analysis, and carefully controlled in vivo validation.
-
DiscoveryProbe Natural Product Library Plus
2026-09-08
The DiscoveryProbe Natural Product Library Plus can be used as a structured bridge from natural product screening for drug discovery to mechanism-focused validation. This article develops an assay strategy inspired by CpAdhE inhibition research while addressing hit confirmation, cellular translation, and screening artifacts.
-
IL-18-Based Caspase Tools Reveal Shared Specificity
2026-09-08
A 2025 preprint introduces LESD-based peptide tools derived from the IL-18 cleavage sequence and shows that inflammatory and apoptotic initiator caspases can share substrate and inhibitor preferences. The study also identifies measurable caspase-8 inhibition by VX-765, emphasizing the need for matched enzyme activity, concentration, and orthogonal controls in caspase experiments.